Helicase Inhibitors as Specifically Targeted Antiviral Therapy for Hepatitis c

Abstract excerpt

The hepatitis C virus (HCV) leads to chronic liver disease and affects more than 2% of the world's population. Complications of the disease include fibrosis, cirrhosis and hepatocellular carcinoma. Current therapy for chronic HCV infection, a combination of ribavirin and pegylated IFN-alpha, is expensive, causes profound side effects and is only moderately effective against several common HCV strains....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hepatitis B Virus Studies
• Share to Hepatitis C virus research
• Share to Liver Disease Diagnosis and Treatment